GlassScriptPhysician profile
Carolyn T Gray
NPI 1740390384
$2,380.25
in general payments reported to CMS, 2019-2025
30 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $578 · 2023: $699 · 2024: $638 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $338.07 | 2021-2024 | Reblozyl, Onureg |
| Astellas Pharma US INC | $266.79 | 2021-2024 | Cresemba |
| Janssen Scientific Affairs, LLC | $191.15 | 2021-2024 | Darzalex, Carvykti, Tecvayli |
| Incyte Corporation | $182.95 | 2021-2023 | Jakafi, Monjuvi |
| Abbvie INC. | $149.90 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $147.74 | 2022-2023 | Imbruvica |
| Seagen INC. | $131.37 | 2021-2023 | Adcetris |
| Amgen INC. | $131.16 | 2021-2024 | Blincyto, Kyprolis |
| Novartis Pharmaceuticals Corporation | $77.01 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $72.64 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.05 | 2021-2025 | Iclusig |
| Paratek Pharmaceuticals, INC. | $64.78 | 2022-2023 | Nuzyra |
| Janssen Biotech, INC. | $62.59 | 2023-2024 | Darzalex, Tecvayli, Talvey |
| Karyopharm Therapeutics INC. | $58.18 | 2022-2023 | Xpovio |
| Morphosys, US INC. | $52.36 | 2022-2023 | Monjuvi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $48.85 | 2023-2024 | Carvykti |
| Alexion Pharmaceuticals, INC. | $42.09 | 2023-2024 | Ultomiris |
| Adc Therapeutics America, INC. | $41.64 | 2021-2022 | |
| Glaxosmithkline, LLC. | $39.44 | 2021-2024 | Ojjaara |
| Genentech USA, INC. | $25.60 | 2023 | Venclexta |
| Merck Sharp & Dohme LLC | $24.47 | 2024 | Zerbaxa, Dificid, Prevymis |
| Invivyd INC | $23.78 | 2025 | Pemgarda |
| Biolinerx USA, INC. | $22.16 | 2024 | Aphexda |
| Syndax Pharmaceuticals, INC. | $19.96 | 2025 | |
| Jazz Pharmaceuticals INC. | $16.92 | 2022 | |
| Sobi, INC | $16.80 | 2024 | |
| Melinta Therapeutics, LLC | $16.24 | 2023 | Vabomere, Rezzayo |
| Servier Pharmaceuticals LLC | $15.34 | 2021 | |
| Acrotech Biopharma INC. | $14.94 | 2023 | Beleodaq |
| Kite Pharma, INC. | $14.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.